Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 13/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | BMX | P51813 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18612934 | 0.85 | FGFR4 (0.41) | FGFR4FGFR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20706003 | 0.84 | FGFR4 (0.63) | FGFR4FGFR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20705997 | 0.83 | FGFR4 (0.44) | FGFR4FGFR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15434002 | 0.69 | FGFR4 (0.49) | FGFR4FGFR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15434004 | 0.69 | FGFR4 (0.62) | FGFR4 | |
| SCHEMBL20705996 | 0.69 | FGFR1 (0.64) | FGFR4FGFR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21756534 | 0.67 | CYP19A1 (0.36) | FGFR4CSF1R | |
| SCHEMBL15413641 | 0.64 | FGFR4 (0.40) | FGFR4FGFR1 | |
| SCHEMBL15413640 | 0.64 | FGFR4 (0.40) | FGFR4FGFR1 | |
| SCHEMBL15611171 | 0.64 | FGFR4 (0.59) | FGFR4CYP3A4CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196436-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196436-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885FGFR1 1/4885CYP3A4 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.